<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">37112878</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>12</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>12</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1999-4915</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>4</Issue><PubDate><Year>2023</Year><Month>Mar</Month><Day>31</Day></PubDate></JournalIssue><Title>Viruses</Title><ISOAbbreviation>Viruses</ISOAbbreviation></Journal><ArticleTitle>Antibody Response to the SARS-CoV-2 Spike and Nucleocapsid Proteins in Patients with Different COVID-19 Clinical Profiles.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">898</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/v15040898</ELocationID><Abstract><AbstractText>The first case of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), in Brazil was diagnosed on February 26, 2020. Due to the important epidemiological impact of COVID-19, the present study aimed to analyze the specificity of IgG antibody responses to the S1, S2 and N proteins of SARS-CoV-2 in different COVID-19 clinical profiles. This study enrolled 136 individuals who were diagnosed with or without COVID-19 based on clinical findings and laboratory results and classified as asymptomatic or as having mild, moderate or severe disease. Data collection was performed through a semistructured questionnaire to obtain demographic information and main clinical manifestations. IgG antibody responses to the S1 and S2 subunits of the spike (S) protein and the nucleocapsid (N) protein were evaluated using an enzyme-linked immunosorbent assay (ELISA) according to the manufacturer's instructions. The results showed that among the participants, 87.5% (119/136) exhibited IgG responses to the S1 subunit and 88.25% (120/136) to N. Conversely, only 14.44% of the subjects (21/136) displayed S2 subunit responses. When analyzing the IgG antibody response while considering the different proteins of the virus, patients with severe disease had significantly higher antibody responses to N and S1 than asymptomatic individuals (<i>p</i> &#x2264; 0.0001), whereas most of the participants had low antibody titers against the S2 subunit. In addition, individuals with long COVID-19 showed a greater IgG response profile than those with symptomatology of a short duration. Based on the results of this study, it is concluded that levels of IgG antibodies may be related to the clinical evolution of COVID-19, with high levels of IgG antibodies against S1 and N in severe cases and in individuals with long COVID-19.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Soares</LastName><ForeName>Sinei Ramos</ForeName><Initials>SR</Initials><AffiliationInfo><Affiliation>Laborat&#xf3;rio de Virologia, Instituto de Ci&#xea;ncias Biol&#xf3;gicas, Universidade Federal do Par&#xe1;, Bel&#xe9;m 66075-110, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>da Silva Torres</LastName><ForeName>Maria Karoliny</ForeName><Initials>MK</Initials><AffiliationInfo><Affiliation>Laborat&#xf3;rio de Virologia, Instituto de Ci&#xea;ncias Biol&#xf3;gicas, Universidade Federal do Par&#xe1;, Bel&#xe9;m 66075-110, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Programa de P&#xf3;s-Gradua&#xe7;&#xe3;o em Biologia de Agentes Infecciosos e Parasit&#xe1;rios, Universidade Federal do Par&#xe1;, Bel&#xe9;m 66075-110, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lima</LastName><ForeName>Sandra Souza</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>Laborat&#xf3;rio de Virologia, Instituto de Ci&#xea;ncias Biol&#xf3;gicas, Universidade Federal do Par&#xe1;, Bel&#xe9;m 66075-110, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Sarges</LastName><ForeName>Kevin Matheus Lima</ForeName><Initials>KML</Initials><Identifier Source="ORCID">0000-0003-0776-6212</Identifier><AffiliationInfo><Affiliation>Laborat&#xf3;rio de Gen&#xe9;tica de Doen&#xe7;as Complexas, Instituto de Ci&#xea;ncias Biol&#xf3;gicas, Universidade Federal do Par&#xe1;, Bel&#xe9;m 66075-110, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Santos</LastName><ForeName>Erika Ferreira Dos</ForeName><Initials>EFD</Initials><Identifier Source="ORCID">0000-0001-9188-1066</Identifier><AffiliationInfo><Affiliation>Laborat&#xf3;rio de Gen&#xe9;tica de Doen&#xe7;as Complexas, Instituto de Ci&#xea;ncias Biol&#xf3;gicas, Universidade Federal do Par&#xe1;, Bel&#xe9;m 66075-110, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Brito</LastName><ForeName>Mioni Thieli Figueiredo Magalh&#xe3;es</ForeName><Initials>MTFM</Initials><Identifier Source="ORCID">0000-0001-8165-8629</Identifier><AffiliationInfo><Affiliation>Laborat&#xf3;rio de Gen&#xe9;tica de Doen&#xe7;as Complexas, Instituto de Ci&#xea;ncias Biol&#xf3;gicas, Universidade Federal do Par&#xe1;, Bel&#xe9;m 66075-110, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>da Silva</LastName><ForeName>Andr&#xe9;a Luciana Soares</ForeName><Initials>ALS</Initials><Identifier Source="ORCID">0000-0003-4299-0252</Identifier><AffiliationInfo><Affiliation>Laborat&#xf3;rio de Gen&#xe9;tica de Doen&#xe7;as Complexas, Instituto de Ci&#xea;ncias Biol&#xf3;gicas, Universidade Federal do Par&#xe1;, Bel&#xe9;m 66075-110, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Meira Leite</LastName><ForeName>Mauro</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-3620-3470</Identifier><AffiliationInfo><Affiliation>Laborat&#xf3;rio de Gen&#xe9;tica de Doen&#xe7;as Complexas, Instituto de Ci&#xea;ncias Biol&#xf3;gicas, Universidade Federal do Par&#xe1;, Bel&#xe9;m 66075-110, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>da Costa</LastName><ForeName>Fl&#xe1;via P&#xf3;voa</ForeName><Initials>FP</Initials><Identifier Source="ORCID">0000-0002-5667-0754</Identifier><AffiliationInfo><Affiliation>Laborat&#xf3;rio de Gen&#xe9;tica de Doen&#xe7;as Complexas, Instituto de Ci&#xea;ncias Biol&#xf3;gicas, Universidade Federal do Par&#xe1;, Bel&#xe9;m 66075-110, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cantanhede</LastName><ForeName>Marcos Henrique Damasceno</ForeName><Initials>MHD</Initials><AffiliationInfo><Affiliation>Laborat&#xf3;rio de Gen&#xe9;tica de Doen&#xe7;as Complexas, Instituto de Ci&#xea;ncias Biol&#xf3;gicas, Universidade Federal do Par&#xe1;, Bel&#xe9;m 66075-110, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>da Silva</LastName><ForeName>Rosilene</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0001-8913-2971</Identifier><AffiliationInfo><Affiliation>Laborat&#xf3;rio de Gen&#xe9;tica de Doen&#xe7;as Complexas, Instituto de Ci&#xea;ncias Biol&#xf3;gicas, Universidade Federal do Par&#xe1;, Bel&#xe9;m 66075-110, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Oliveira Lameira Ver&#xed;ssimo</LastName><ForeName>Adriana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Hospital Adventista de Bel&#xe9;m, Bel&#xe9;m 66093-904, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vallinoto</LastName><ForeName>Izaura Maria Vieira Cayres</ForeName><Initials>IMVC</Initials><AffiliationInfo><Affiliation>Laborat&#xf3;rio de Virologia, Instituto de Ci&#xea;ncias Biol&#xf3;gicas, Universidade Federal do Par&#xe1;, Bel&#xe9;m 66075-110, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Programa de P&#xf3;s-Gradua&#xe7;&#xe3;o em Biologia de Agentes Infecciosos e Parasit&#xe1;rios, Universidade Federal do Par&#xe1;, Bel&#xe9;m 66075-110, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feitosa</LastName><ForeName>Rosimar Neris Martins</ForeName><Initials>RNM</Initials><Identifier Source="ORCID">0000-0003-2044-9350</Identifier><AffiliationInfo><Affiliation>Laborat&#xf3;rio de Virologia, Instituto de Ci&#xea;ncias Biol&#xf3;gicas, Universidade Federal do Par&#xe1;, Bel&#xe9;m 66075-110, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Programa de P&#xf3;s-Gradua&#xe7;&#xe3;o em Biologia de Agentes Infecciosos e Parasit&#xe1;rios, Universidade Federal do Par&#xe1;, Bel&#xe9;m 66075-110, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quaresma</LastName><ForeName>Juarez Ant&#xf4;nio Sim&#xf5;es</ForeName><Initials>JAS</Initials><AffiliationInfo><Affiliation>Programa de P&#xf3;s-Gradua&#xe7;&#xe3;o em Biologia de Agentes Infecciosos e Parasit&#xe1;rios, Universidade Federal do Par&#xe1;, Bel&#xe9;m 66075-110, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Ci&#xea;ncias Biol&#xf3;gicas e da Sa&#xfa;de, Universidade do Estado do Par&#xe1;, Bel&#xe9;m 66050-540, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chaves</LastName><ForeName>T&#xe2;nia do Socorro Souza</ForeName><Initials>TDSS</Initials><AffiliationInfo><Affiliation>Laborat&#xf3;rio de Pesquisas B&#xe1;sicas em Mal&#xe1;ria em Mal&#xe1;ria, Se&#xe7;&#xe3;o de Parasitologia, Instituto Evandro Chagas, Secretaria de Ci&#xea;ncia, Tecnologia e Insumos Estrat&#xe9;gicos, Minist&#xe9;rio da Sa&#xfa;de do Brasil, Ananindeua 70068-900, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Viana</LastName><ForeName>Giselle Maria Rachid</ForeName><Initials>GMR</Initials><AffiliationInfo><Affiliation>Programa de P&#xf3;s-Gradua&#xe7;&#xe3;o em Biologia de Agentes Infecciosos e Parasit&#xe1;rios, Universidade Federal do Par&#xe1;, Bel&#xe9;m 66075-110, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laborat&#xf3;rio de Pesquisas B&#xe1;sicas em Mal&#xe1;ria em Mal&#xe1;ria, Se&#xe7;&#xe3;o de Parasitologia, Instituto Evandro Chagas, Secretaria de Ci&#xea;ncia, Tecnologia e Insumos Estrat&#xe9;gicos, Minist&#xe9;rio da Sa&#xfa;de do Brasil, Ananindeua 70068-900, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Falc&#xe3;o</LastName><ForeName>Luiz F&#xe1;bio Magno</ForeName><Initials>LFM</Initials><Identifier Source="ORCID">0000-0001-8391-2694</Identifier><AffiliationInfo><Affiliation>Centro de Ci&#xea;ncias Biol&#xf3;gicas e da Sa&#xfa;de, Universidade do Estado do Par&#xe1;, Bel&#xe9;m 66050-540, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Santos</LastName><ForeName>Eduardo Jos&#xe9; Melo Dos</ForeName><Initials>EJMD</Initials><Identifier Source="ORCID">0000-0001-5134-5648</Identifier><AffiliationInfo><Affiliation>Laborat&#xf3;rio de Gen&#xe9;tica de Doen&#xe7;as Complexas, Instituto de Ci&#xea;ncias Biol&#xf3;gicas, Universidade Federal do Par&#xe1;, Bel&#xe9;m 66075-110, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vallinoto</LastName><ForeName>Antonio Carlos Ros&#xe1;rio</ForeName><Initials>ACR</Initials><Identifier Source="ORCID">0000-0003-1135-6507</Identifier><AffiliationInfo><Affiliation>Laborat&#xf3;rio de Virologia, Instituto de Ci&#xea;ncias Biol&#xf3;gicas, Universidade Federal do Par&#xe1;, Bel&#xe9;m 66075-110, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>da Silva</LastName><ForeName>Andr&#xe9;a Nazar&#xe9; Monteiro Rangel</ForeName><Initials>ANMR</Initials><AffiliationInfo><Affiliation>Laborat&#xf3;rio de Virologia, Instituto de Ci&#xea;ncias Biol&#xf3;gicas, Universidade Federal do Par&#xe1;, Bel&#xe9;m 66075-110, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Programa de P&#xf3;s-Gradua&#xe7;&#xe3;o em Biologia de Agentes Infecciosos e Parasit&#xe1;rios, Universidade Federal do Par&#xe1;, Bel&#xe9;m 66075-110, Brazil.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Viruses</MedlineTA><NlmUniqueID>101509722</NlmUniqueID><ISSNLinking>1999-4915</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019590">Nucleocapsid Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000657845">spike protein, SARS-CoV-2</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000917" MajorTopicYN="N">Antibody Formation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019590" MajorTopicYN="N">Nucleocapsid Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">IgG antibodies</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">immunity</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>2</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>3</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>1</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>28</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>28</Day><Hour>1</Hour><Minute>54</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>3</Month><Day>31</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37112878</ArticleId><ArticleId IdType="pmc">PMC10141342</ArticleId><ArticleId IdType="doi">10.3390/v15040898</ArticleId><ArticleId IdType="pii">v15040898</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>National Health Commission of the People&#x2019;s Republic of China  Update on the Novel Coronavirus Pneumonia Outbreak.  [(accessed on 27 March 2020)];2020  Available online:  http://www.nhc.gov.cn/xcs/yqtb/list_gzbd.shtml.</Citation></Reference><Reference><Citation>World Health Organization  Coronavirus Disease (COVID-2019) Situation Reports.  [(accessed on 27 March 2020)];2020  Available online:  https://www.who.int/emergencies/diseases/novel--coronavirus2019/situation--reports/</Citation></Reference><Reference><Citation>Corman V.M., Muth D., Niemeyer D., Drosten C. Hosts and Sources of Endemic Human Coronaviruses. Adv. Virus Res. 2018;100:163&#x2013;188. doi: 10.1016/bs.aivir.2018.01.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/bs.aivir.2018.01.001</ArticleId><ArticleId IdType="pmc">PMC7112090</ArticleId><ArticleId IdType="pubmed">29551135</ArticleId></ArticleIdList></Reference><Reference><Citation>Rastogi M., Pandey N., Shukla A., Singh S.K. SARS coronavirus 2: From genome to infectome. Respir. Res. 2020;21:318. doi: 10.1186/s12931-020-01581-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12931-020-01581-z</ArticleId><ArticleId IdType="pmc">PMC7706175</ArticleId><ArticleId IdType="pubmed">33261606</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M.Y., Zhao R., Gao L.J., Gao X.F., Wang D.P., Cao J.M. SARS-CoV-2: Structure, Biology, and Structure-Based Therapeutics Development. Front. Cell. Infect. Microbiol. 2020;10:587269. doi: 10.3389/fcimb.2020.587269.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2020.587269</ArticleId><ArticleId IdType="pmc">PMC7723891</ArticleId><ArticleId IdType="pubmed">33324574</ArticleId></ArticleIdList></Reference><Reference><Citation>Walls A.C., Park Y.J., Tortorici M.A., Wall A., McGuire A.T., Veesler D. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell. 2020;181:281&#x2013;292.e6. doi: 10.1016/j.cell.2020.02.058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.02.058</ArticleId><ArticleId IdType="pmc">PMC7102599</ArticleId><ArticleId IdType="pubmed">32155444</ArticleId></ArticleIdList></Reference><Reference><Citation>Lan J., Yao Y., Deng Y., Chen H., Lu G., Wang W., Bao L., Deng W., Wei Q., Gao G.F., et al. Recombinant Receptor Binding Domain Protein Induces Partial Protective Immunity in Rhesus Macaques Against Middle East Respiratory Syndrome Coronavirus Challenge. eBioMedicine. 2015;2:1438&#x2013;1446. doi: 10.1016/j.ebiom.2015.08.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2015.08.031</ArticleId><ArticleId IdType="pmc">PMC4634622</ArticleId><ArticleId IdType="pubmed">26629538</ArticleId></ArticleIdList></Reference><Reference><Citation>Cong Y., Ulasli M., Schepers H., Mauthe M., V&#x2019;Kovski P., Kriegenburg F., Thiel V., de Haan C.A.M., Reggiori F. Nucleocapsid protein recruitment to replication-transcription complexes plays a crucial role in coronaviral life cycle. J. Virol. 2020;94:e01925-19. doi: 10.1128/JVI.01925-19.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01925-19</ArticleId><ArticleId IdType="pmc">PMC6997762</ArticleId><ArticleId IdType="pubmed">31776274</ArticleId></ArticleIdList></Reference><Reference><Citation>Leung D.T., Tam F.C., Ma C.H., Chan P.K., Cheung J.L., Niu H., Tam J.S., Lim P.L. Antibody response of patients with severe acute respiratory syndrome (SARS) targets the viral nucleocapsid. J. Infect. Dis. 2004;190:379&#x2013;386. doi: 10.1086/422040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/422040</ArticleId><ArticleId IdType="pmc">PMC7110057</ArticleId><ArticleId IdType="pubmed">15216476</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong Y., Dai T., Wei Y., Zhang L., Zheng M., Zhou F. A systematic review of SARS-CoV-2 vaccine candidates. Signal Transduct. Target. Ther. 2020;5:237. doi: 10.1038/s41392-020-00352-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-020-00352-y</ArticleId><ArticleId IdType="pmc">PMC7551521</ArticleId><ArticleId IdType="pubmed">33051445</ArticleId></ArticleIdList></Reference><Reference><Citation>Li D., Li J. Immunologic Testing for SARS-CoV-2 Infection from the Antigen Perspective. J. Clin. Microbiol. 2021;59:e02160-20. doi: 10.1128/JCM.02160-20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.02160-20</ArticleId><ArticleId IdType="pmc">PMC8091849</ArticleId><ArticleId IdType="pubmed">33318065</ArticleId></ArticleIdList></Reference><Reference><Citation>Xavier A.R., Silva J.S., Almeida J.P., Concei&#xe7;&#xe3;o J.F., Lacerda J.S., Kannan S. COVID-19: Clinical and laboratory manifestations in novel coronavirus infection. J. Bras. Patol. Med. Lab. 2020;56:e3232020. doi: 10.5935/1676-2444.20200049.</Citation><ArticleIdList><ArticleId IdType="doi">10.5935/1676-2444.20200049</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization (WHO)  Q&amp;A: Similarities and Differences&#x2014;COVID-19 and Influenza.  [(accessed on 27 March 2020)];2020  Available online:  https://www.who.int/news-room/q-a-detail/q-asimilarities-and-differences-COVID-19-and-influenza.</Citation></Reference><Reference><Citation>Proal A.D., VanElzakker M.B. Long COVID or Post-acute Sequelae of COVID-19 (PASC): An Overview of Biological Factors That May Contribute to Persistent Symptoms. Front. Microbiol. 2021;12:698169. doi: 10.3389/fmicb.2021.698169.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2021.698169</ArticleId><ArticleId IdType="pmc">PMC8260991</ArticleId><ArticleId IdType="pubmed">34248921</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J., Li D., Cameron A., Zhou Q., Wiltse A., Nayak J., Pecora N.D., Zand M.S. IgG Against Human Betacoronavirus Spike Proteins Correlates With SARS-CoV-2 Anti-Spike IgG Responses and COVID-19 Disease Severity. J. Infect. Dis. 2022;226:474&#x2013;484. doi: 10.1093/infdis/jiac022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiac022</ArticleId><ArticleId IdType="pmc">PMC8807312</ArticleId><ArticleId IdType="pubmed">35091739</ArticleId></ArticleIdList></Reference><Reference><Citation>Queiroz M.A.F., Neves P.F.M.D., Lima S.S., Lopes J.D.C., Torres M.K.D.S., Vallinoto I.M.V.C., Bichara C.D.A., Dos Santos E.F., de Brito M.T.F.M., da Silva A.L.S., et al. Cytokine Profiles Associated with Acute COVID-19 and Long COVID-19 Syndrome. Front. Cell. Infect. Microbiol. 2022;12:922422. doi: 10.3389/fcimb.2022.922422.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2022.922422</ArticleId><ArticleId IdType="pmc">PMC9279918</ArticleId><ArticleId IdType="pubmed">35846757</ArticleId></ArticleIdList></Reference><Reference><Citation>Mart&#x131;nez-Flores D., Zepeda-Cervantes J., Cruz-Rese&#x2019;ndiz A., Aguirre-Sampieri S., Sampieri A., Vaca L. SARS-CoV-2 Vaccines Based on the Spike Glycoprotein and Implications of New Viral Variants. Front. Immunol. 2021;12:701501. doi: 10.3389/fimmu.2021.701501.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.701501</ArticleId><ArticleId IdType="pmc">PMC8311925</ArticleId><ArticleId IdType="pubmed">34322129</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheikhshahrokh A., Ranjbar R., Saeidi E., Safarpoor Dehkordi F., Heiat M., Ghasemi-Dehkordi P., Goodarzi H. Frontier Therapeutics and Vaccine Strategies for SARS-CoV-2 (COVID-19): A Review. Iran. J. Public Health. 2020;49:18&#x2013;29. doi: 10.18502/ijph.v49iS1.3666.</Citation><ArticleIdList><ArticleId IdType="doi">10.18502/ijph.v49iS1.3666</ArticleId><ArticleId IdType="pmc">PMC8266011</ArticleId><ArticleId IdType="pubmed">34268202</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization (WHO)  Clinical Management of COVID 19: Interim Guidance, 27 May 2020.  [(accessed on 23 February 2023)]; Available online:  https://apps.who.int/iris/handle/10665/332196.</Citation></Reference><Reference><Citation>Shrock E., Fujimura E., Kula T., Timms R.T., Lee I.H., Leng Y., Robinson M.L., Sie B.M., Li M.Z., Chen Y., et al. Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity. Science. 2020;370:eabd4250. doi: 10.1126/science.abd4250.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abd4250</ArticleId><ArticleId IdType="pmc">PMC7857405</ArticleId><ArticleId IdType="pubmed">32994364</ArticleId></ArticleIdList></Reference><Reference><Citation>Lauxmann M.A., Santucci N.E., Autran-Gomez A.M. The SARS-CoV-2 Coronavirus and the COVID-19 Outbreak. Acad. Bras. Ci&#xea;nc. 2020;92:e20200709. doi: 10.1590/s1677-5538.ibju.2020.s101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/s1677-5538.ibju.2020.s101</ArticleId><ArticleId IdType="pmc">PMC7719995</ArticleId><ArticleId IdType="pubmed">32549071</ArticleId></ArticleIdList></Reference><Reference><Citation>R&#xf6;ltgen K., Boyd S.D. Antibody and B cell responses to SARS-CoV-2 infection and vaccination. Cell. Host Microbe. 2020;29:1063&#x2013;1075. doi: 10.1016/j.chom.2021.06.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2021.06.009</ArticleId><ArticleId IdType="pmc">PMC8233571</ArticleId><ArticleId IdType="pubmed">34174992</ArticleId></ArticleIdList></Reference><Reference><Citation>Smits V.A.J., Hern&#xe1;ndez-Carralero E., Paz-Cabrer M.C., Cabrera E. The Nucleocapsid protein triggers the main humoral immune response in COVID-19 patients. Biochem. Biophys. Res. Commun. 2021;543:45&#x2013;49. doi: 10.1016/j.bbrc.2021.01.073.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2021.01.073</ArticleId><ArticleId IdType="pmc">PMC7825866</ArticleId><ArticleId IdType="pubmed">33515911</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng K.T., Mohd-Ismail N.K., Tan Y.J. Spike S2 Subunit: The Dark Horse in the Race for Prophylactic and Therapeutic Interventions against SARS-CoV-2. Vaccines. 2021;9:178. doi: 10.3390/vaccines9020178.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines9020178</ArticleId><ArticleId IdType="pmc">PMC7923282</ArticleId><ArticleId IdType="pubmed">33672450</ArticleId></ArticleIdList></Reference><Reference><Citation>Mari&#xeb;n J., Ceulemans A., Michiels J., Heyndrickx L. Evaluating SARS-CoV-2 spike and nucleocapsid proteins as targets for antibody detection in severe and mild COVID-19 cases using a Luminex bead-based assay. J. Virol. Methods. 2021;288:114025. doi: 10.1016/j.jviromet.2020.114025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jviromet.2020.114025</ArticleId><ArticleId IdType="pmc">PMC7678438</ArticleId><ArticleId IdType="pubmed">33227340</ArticleId></ArticleIdList></Reference><Reference><Citation>Long Q.X., Liu B.Z., Deng H.J., Wu G.C., Deng K., Chen Y.K., Liao P., Qiu J.F., Lin Y., Cai X.F., et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat. Med. 2020;26:845&#x2013;848. doi: 10.1038/s41591-020-0897-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0897-1</ArticleId><ArticleId IdType="pubmed">32350462</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao B., Chen Z., Zheng P., Li L., Zhuo J., Li F., Li S., Chen D., Wen C., Cai W., et al. Detection of Anti-SARS-CoV-2-S2 IgG Is More Sensitive Than Anti-RBD IgG in Identifying Asymptomatic COVID-19 Patients. Front. Immunol. 2021;12:724763. doi: 10.3389/fimmu.2021.724763.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.724763</ArticleId><ArticleId IdType="pmc">PMC8416675</ArticleId><ArticleId IdType="pubmed">34489978</ArticleId></ArticleIdList></Reference><Reference><Citation>Iyer A.S., Jones F.K., Nodoushani A., Kelly M. Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients. Sci. Immunol. 2020;5:eabe0367. doi: 10.1126/sciimmunol.abe0367.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abe0367</ArticleId><ArticleId IdType="pmc">PMC7857394</ArticleId><ArticleId IdType="pubmed">33033172</ArticleId></ArticleIdList></Reference><Reference><Citation>Bichara C.D.A., da Silva G.A.E., Vaz G.L., da Silva T.M.K., Queiroz M.A.F., do Amaral I.P.C., Vallinoto I.M.V.C., Bichara C.N.C., Vallinoto A.C.R. Dynamics of anti-SARS-CoV-2 IgG antibodies post-COVID-19 in a Brazilian Amazon population. BMC Infect. Dis. 2021;21:443. doi: 10.1186/s12879-021-06156-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-021-06156-x</ArticleId><ArticleId IdType="pmc">PMC8122196</ArticleId><ArticleId IdType="pubmed">33992073</ArticleId></ArticleIdList></Reference><Reference><Citation>Legros V., Denolly S., Vogrig M., Boson B. A longitudinal study of SARS-CoV-2-infected patients reveals a high correlation between neutralizing antibodies and COVID-19 severity. Cell. Mol. Immunol. 2021;18:318&#x2013;327. doi: 10.1038/s41423-020-00588-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41423-020-00588-2</ArticleId><ArticleId IdType="pmc">PMC7786875</ArticleId><ArticleId IdType="pubmed">33408342</ArticleId></ArticleIdList></Reference><Reference><Citation>Karthik K., Senthilkumar T.M.A., Udhayavel S., Raj G.D. Role of antibody-dependent enhancement (ADE) in the virulence of SARS-CoV-2 and its mitigation strategies for the development of vaccines and immunotherapies to counter COVID-19. Hum. Vaccines Immunother. 2020;16:3055&#x2013;3060. doi: 10.1080/21645515.2020.1796425.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2020.1796425</ArticleId><ArticleId IdType="pmc">PMC7484565</ArticleId><ArticleId IdType="pubmed">32845733</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y., Soh W.T., Kishikawa J.I., Hirose M., Nakayama E.E., Li S., Sasai M., Suzuki T., Tada A., Arakawa A., et al. An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies. Cell. 2021;184:3452&#x2013;3466.e18. doi: 10.1016/j.cell.2021.05.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.05.032</ArticleId><ArticleId IdType="pmc">PMC8142859</ArticleId><ArticleId IdType="pubmed">34139176</ArticleId></ArticleIdList></Reference><Reference><Citation>Lau E.H.Y., Tsang O.T.Y., Hui D.S.C., Kwan M.Y.W. Neutralizing antibody titres in SARS-CoV-2 infections. Nat. Commun. 2021;12:63. doi: 10.1038/s41467-020-20247-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-20247-4</ArticleId><ArticleId IdType="pmc">PMC7782739</ArticleId><ArticleId IdType="pubmed">33397909</ArticleId></ArticleIdList></Reference><Reference><Citation>Michelen M., Manoharan L., Elkheir N., Cheng V., Dagens A., Hastie C., O&#x2019;Hara M., Suett J., Dahmash D., Bugaeva P., et al. Characterising long COVID: A living systematic review. BMJ Glob. Health. 2021;6:e005427. doi: 10.1136/bmjgh-2021-005427.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjgh-2021-005427</ArticleId><ArticleId IdType="pmc">PMC8478580</ArticleId><ArticleId IdType="pubmed">34580069</ArticleId></ArticleIdList></Reference><Reference><Citation>Jogue J.K., Franko N.M., McCulloch D.J., McDonald D., Magedson A., Wolf C.R., Chu H.Y. Sequelae in Adults at 6 Months After COVID-19 Infection. JAMA Netw. Open. 2021;4:e210830. doi: 10.1001/jamanetworkopen.2021.0830.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.0830</ArticleId><ArticleId IdType="pmc">PMC7896197</ArticleId><ArticleId IdType="pubmed">33606031</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Rio C., Collins L.F., Malani P. Long-term Health Consequences of COVID-19. JAMA. 2020;324:1723&#x2013;1724. doi: 10.1001/jama.2020.19719.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.19719</ArticleId><ArticleId IdType="pmc">PMC8019677</ArticleId><ArticleId IdType="pubmed">33031513</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a-Abell&#xe1;n J., Padilla S., Fern&#xe1;ndez-Gonz&#xe1;lez M., Garc&#xed;a J.A., Agull&#xf3; V., Andreo M., Ruiz S., Galiana A., Guti&#xe9;rrez F., Masi&#xe1; M. Antibody Response to SARS-CoV-2 is Associated with Long-term Clinical Outcome in Patients with COVID-19: A Longitudinal Study. J. Clin. Immunol. 2021;41:1490&#x2013;1501. doi: 10.1007/s10875-021-01083-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10875-021-01083-7</ArticleId><ArticleId IdType="pmc">PMC8285689</ArticleId><ArticleId IdType="pubmed">34273064</ArticleId></ArticleIdList></Reference><Reference><Citation>Woodruff M.C., Ramonell R.P., Haddad N.S., Anam F.A., Rudolph M.E., Walker T.A., Truong A.D., Dixit A.N., Han J.E., Cabrera-Mora M., et al. Dysregulated naive B cells and de novo autoreactivity in severe COVID-19. Nature. 2022;611:139&#x2013;147. doi: 10.1038/s41586-022-05273-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-05273-0</ArticleId><ArticleId IdType="pmc">PMC9630115</ArticleId><ArticleId IdType="pubmed">36044993</ArticleId></ArticleIdList></Reference><Reference><Citation>Sumi T., Harada K. Immune response to SARS-CoV-2 in severe disease and long COVID-19. iScience. 2022;25:104723. doi: 10.1016/j.isci.2022.104723.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2022.104723</ArticleId><ArticleId IdType="pmc">PMC9251893</ArticleId><ArticleId IdType="pubmed">35813874</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>